In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment till ailment progression or perhaps the members are not able to tolerate the study drugs. - "Our study exposed the very important position of the KLF16/MYC regulatory https://messiahbnyiu.activoblog.com/33884289/top-brd4-inhibition-by-abbv-744-in-cancer-research-studies-secrets